Aralez Pharma (ARLZ) Tops Q3 EPS by 5c; Boosts FY16 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Aralez Reports Third Quarter 2016 Financial Results
November 7, 2016 7:15 AM EST-Completed Acquisitions of ZONTIVITY®; Toprol-XL® and its Authorized Generic-
-Received U.S. Food and Drug Administration Approval and Launched YOSPRALA-
-Provides Improved 2016 Full Year Guidance-
MISSISSAUGA, Ontario, Nov. 7, 2016 /PRNewswire/ --Â Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company")Â today announced financial results for the third quarter ended September 30, 2016. The Company also highlighted certain corporate and commercial updates. All figures are in U.S. dollars.
Corporate Updates:
On October... More